CVRS - Corindus Vascular Robotics, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD
2.7900
+0.1200 (+4.49%)
At close: 4:00PM EDT

2.8000 +0.01 (0.36%)
After hours: 6:05PM EDT

Stock chart is not supported by your current browser
Previous Close2.6700
Open2.6700
Bid0.0000 x 2200
Ask0.0000 x 2900
Day's Range2.6500 - 2.7900
52 Week Range0.7800 - 3.4900
Volume877,973
Avg. Volume1,915,247
Market Cap576.693M
Beta (3Y Monthly)1.88
PE Ratio (TTM)N/A
EPS (TTM)-0.1970
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.90
Trade prices are not sourced from all markets
  • Business Wire4 days ago

    Corindus Adds Two New CorPath GRX Installations to HCA Healthcare Facilities

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it has installed CorPath® GRX Systems in two new hospitals affiliated with one of the nation’s largest hospital networks, HCA Healthcare. The new systems are now installed in hospital locations in Florida and Texas, bringing the total number of HCA hospitals utilizing CorPath GRX to three.

  • Business Wire5 days ago

    Corindus Announces Regulatory Approval of CorPath GRX for Neurovascular Intervention in Australia and New Zealand

    Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that it received approval from the Australian Therapeutic Goods Administration to commercialize its CorPath® GRX System for neurovascular interventions in Australia and New Zealand. The CorPath GRX System is already approved for percutaneous coronary and peripheral vascular interventions in the region.

  • Business Wire13 days ago

    Corindus Announces First Commercial Installation of CorPath® GRX System in South America

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Albert Einstein Jewish Hospital (Hospital Israelita Albert Einstein) in São Paulo, Brazil has become the first hospital in the Southern Hemisphere to implement Corindus’ CorPath GRX System. Ranked as the best hospital in Latin America for 10 years in a row, Albert Einstein Jewish Hospital will continue to uphold its standing by leveraging the Company's technology in its health system’s leading research facilities.

  • Business Wire21 days ago

    Corindus Joins Russell 3000® Index

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, today announced that the Company will join the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 10, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.

  • Do Directors Own Corindus Vascular Robotics, Inc. (NYSEMKT:CVRS) Shares?
    Simply Wall St.last month

    Do Directors Own Corindus Vascular Robotics, Inc. (NYSEMKT:CVRS) Shares?

    A look at the shareholders of Corindus Vascular Robotics, Inc. (NYSEMKT:CVRS) can tell us which group is most...

  • Are Corindus Vascular Robotics, Inc.'s (NYSEMKT:CVRS) Interest Costs Too High?
    Simply Wall St.last month

    Are Corindus Vascular Robotics, Inc.'s (NYSEMKT:CVRS) Interest Costs Too High?

    Corindus Vascular Robotics, Inc. (NYSEMKT:CVRS) is a small-cap stock with a market capitalization of US$620m. While...

  • Business Wire2 months ago

    Corindus CorPath GRX System Successfully Used in Live Complex Robotic-Assisted Coronary Intervention at EuroPCR 2019

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today its CorPath® GRX System was successfully used to perform a live complex robotic-assisted percutaneous coronary intervention (PCI) at the EuroPCR 2019 Conference in Paris, France on Wednesday, May 22, 2019. Interventional Cardiologist, PCR Vice-Chairman, and Course Director of EuroPCR, Dr. Jean Fajadet performed the procedure from Clinique Pasteur in Toulouse, France.

  • Business Wire2 months ago

    Corindus to Showcase CorPath® GRX Robotic System at EuroPCR 2019

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it will showcase advanced robotic capabilities of the CorPath GRX System at EuroPCR 2019 in Paris, France from May 21-24, 2019. Corindus will use the annual meeting at EuroPCR 2019 to highlight recent milestones in technology development, including the latest CE marked technIQ™ Smart Procedural Automation, automated movements aimed at improving navigation, lesion crossing, and delivery of therapy.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CVRS.A earnings conference call or presentation 7-May-19 8:30pm GMT

    Q1 2019 Corindus Vascular Robotics Inc Earnings Call

  • Why Corindus Vascular Robotics Is Soaring Today
    Motley Fool2 months ago

    Why Corindus Vascular Robotics Is Soaring Today

    Shares jump even though its first-quarter results fell short of Wall Street's estimates. What can explain the optimism?

  • Corindus Vascular Robotics (CVRS) Reports Q1 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Corindus Vascular Robotics (CVRS) Reports Q1 Loss, Tops Revenue Estimates

    Corindus Vascular (CVRS) delivered earnings and revenue surprises of 0.00% and 4.69%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Corindus Vascular: 1Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 5 cents per share. The vascular robotic-assisted systems developer posted revenue of $3 million in the period. In the final minutes of trading ...

  • Business Wire2 months ago

    Corindus Reports First Quarter 2019 Results

    Eleven purchase orders for CorPath GRX Systems as adoption grows

  • ACCESSWIRE2 months ago

    Corindus Vascular Robotics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 7, 2019 / Corindus Vascular Robotics, Inc. (NYSE American: CVRS ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 7, 2019 ...

  • Business Wire2 months ago

    Corindus Equips the World’s First Fully Robotic Catheterization Laboratory

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Chesapeake Regional Healthcare in Chesapeake, VA has equipped both of its catheterization labs at Chesapeake Regional Medical Center with CorPath GRX Vascular Robotic Systems, making it the first hospital in the world to adopt vascular robotic systems in all vascular intervention treatment rooms. The outfitted labs will allow physicians to leverage the latest robotic technology for percutaneous coronary intervention (PCI) and peripheral vascular intervention (PVI) and provide all patients requiring these procedures at Chesapeake Regional access to the latest technology in cardiovascular disease care.

  • Will Corindus Vascular Robotics (CVRS) Report Negative Earnings Next Week? What You Should Know
    Zacks3 months ago

    Will Corindus Vascular Robotics (CVRS) Report Negative Earnings Next Week? What You Should Know

    Corindus Vascular (CVRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire3 months ago

    Corindus to Report First Quarter 2019 Financial Results on May 7, 2019

    Corindus Vascular Robotics, Inc. , a leading developer of precision vascular robotics, today announced that it will release first quarter 2019 financial and business results on Tuesday, May 7, 2019 after the close of the U.S.

  • Business Wire3 months ago

    Corindus Announces First Robotic-Assisted Interventions in Japan for CorPath GRX Post-Market Study

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that the first clinical robotic-assisted PCI procedures in Japan were completed in partnership with Takafumi Ueno, MD, PhD, Director of Interventional Cardiology, Center of Cardiovascular Disease, Kurume University Hospital. CorPath GRX received Pharmaceutical and Medical Device Agency (PMDA) approval in 2018 and A1 technical fee reimbursement for Japan in March of this year.

  • Business Wire4 months ago

    Corindus Vascular Robotics Files Required Registration Statement for Holders of Recently Completed $19.8 Million Private Placement

    Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that it filed a registration statement on behalf of investors that participated in its recently completed private placement. As previously disclosed, earlier this quarter, Corindus sold shares of its common stock to a large institutional investor and certain existing stockholders with contractual preemptive rights, including Hudson Executive Capital (“HEC”) and BioStar Ventures, for aggregate gross proceeds of approximately $19.8 million. HEC purchased an amount in excess of their allotment under the preemptive rights.

  • These Hedge Funds Were Right Betting On Corindus Vascular Robotics Inc (CVRS)
    Insider Monkey4 months ago

    These Hedge Funds Were Right Betting On Corindus Vascular Robotics Inc (CVRS)

    It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]

  • Why Corindus Vascular Robotics Shares Are Rising Today
    Motley Fool4 months ago

    Why Corindus Vascular Robotics Shares Are Rising Today

    News that an insider is rapidly adding to his position has the stock heading higher.

  • Corindus Vascular Robotics Inc (CVRS) Q4 2018 Earnings Conference Call Transcript
    Motley Fool4 months ago

    Corindus Vascular Robotics Inc (CVRS) Q4 2018 Earnings Conference Call Transcript

    CVRS earnings call for the period ending December 31, 2018.